{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:09:54Z","timestamp":1778670594747,"version":"3.51.4"},"reference-count":62,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate-specific antigen (PSA) is a widely available and analytically robust biomarker, but its role in prostate cancer (PCa) screening remains controversial due to concerns regarding limited specificity, overdiagnosis of indolent tumors, and the downstream risk of overtreatment. This review provides a critical analysis of the main randomized trials, systematic reviews, and meta-analyses that have shaped current recommendations against PSA-based screening, highlighting the substantial methodological heterogeneity that complicates interpretation of aggregated outcomes. Key limitations identified across studies include variability in PSA thresholds and screening intensity, insufficient follow-up in some cases to detect long-term mortality benefits, non-comparability of PSA assays, and extensive contamination of control groups \u2013 particularly in the PLCO trial \u2013 which undermines estimates of screening efficacy. Recent updates from the ERSPC and CAP trials show that mortality reductions associated with screening increase with longer follow-up, supporting the need to reassess earlier conclusions. Parallel to the evolving evidence base, European initiatives such as the PRAISE-U consortium and several regional pilot programs following the European Council\u2019s recommendations are implementing risk-adapted pathways that combine baseline PSA stratification with multiparametric MRI triage and selective biopsy. These programs aim to minimize overdiagnosis while improving detection of clinically significant PCa and generating real-world evidence for organized screening. Additionally, the variability among PSA assays underscores the need for greater harmonization and standardized reporting. Overall, emerging data suggest that intelligently targeted, risk-stratified PSA screening may offer a more balanced approach than the traditional dichotomy of screening vs. no screening.<\/jats:p>","DOI":"10.1515\/almed-2025-0187","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:58:46Z","timestamp":1769497126000},"page":"81-89","source":"Crossref","is-referenced-by-count":0,"title":["The evolving role of PSA in prostate cancer screening: revisiting the evidence in the era of personalized medicine"],"prefix":"10.1515","volume":"7","author":[{"given":"Xavier","family":"Filella","sequence":"first","affiliation":[{"name":"Biochemistry and Molecular Genetics Department , Hospital Clinic , Barcelona , Catalonia , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2026051310150650678_j_almed-2025-0187_ref_001","unstructured":"Molina, R, Filella, X, Ballesta, AM. Marcadores tumorales: teor\u00eda o realidad? Med Clin 1994;102:189\u201395."},{"key":"2026051310150650678_j_almed-2025-0187_ref_002","doi-asserted-by":"crossref","unstructured":"Filella, X, Rodr\u00edguez-Garcia, M, Fern\u00e1ndez-Gal\u00e1n, E. Clinical usefulness of circulating tumor markers. Clin Chem Lab Med 2022;61:895\u2013905.","DOI":"10.1515\/cclm-2022-1090"},{"key":"2026051310150650678_j_almed-2025-0187_ref_003","doi-asserted-by":"crossref","unstructured":"McGinley, PJ, Kilpatrick, ES. Tumour markers: their use and misuse by clinicians. Ann Clin Biochem 2003;40:643\u20137. https:\/\/doi.org\/10.1258\/000456303770367234.","DOI":"10.1258\/000456303770367234"},{"key":"2026051310150650678_j_almed-2025-0187_ref_004","doi-asserted-by":"crossref","unstructured":"Gion, M, Franceschini, R, Rosin, C, Trevisiol, C, Peloso, L, Zappa, M, et al.. Working group on tumour markers of Italian society of clinical biochemistry and clinical molecular biology (SIBioC). An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests. Clin Chem Lab Med 2014;52:889\u201397. https:\/\/doi.org\/10.1515\/cclm-2013-0708.","DOI":"10.1515\/cclm-2013-0708"},{"key":"2026051310150650678_j_almed-2025-0187_ref_005","doi-asserted-by":"crossref","unstructured":"Moreno-Campoy, EE, M\u00e9rida-De la Torre, FJ, Martos-Crespo, F, Plebani, M. Identifying risk in the use of tumor markers to improve patient safety. Clin Chem Lab Med 2016;54:1947\u201353. https:\/\/doi.org\/10.1515\/cclm-2015-0760.","DOI":"10.1515\/cclm-2015-0760"},{"key":"2026051310150650678_j_almed-2025-0187_ref_006","doi-asserted-by":"crossref","unstructured":"Gion, M, Peloso, L, Trevisiol, C, Squarcina, E, Zappa, M, Fabricio, AS, et al.. An epidemiology-based model as a tool to monitor the outbreak of inappropriateness in tumor marker requests: a national scale study. Clin Chem Lab Med 2016;54:473\u201382. https:\/\/doi.org\/10.1515\/cclm-2015-0329.","DOI":"10.1515\/cclm-2015-0329"},{"key":"2026051310150650678_j_almed-2025-0187_ref_007","doi-asserted-by":"crossref","unstructured":"Gilligan, T. Prostate cancer: to screen or not to screen? The question is complicated. Cleve Clin J Med 2021;88:17\u20138. https:\/\/doi.org\/10.3949\/ccjm.88a.20192.","DOI":"10.3949\/ccjm.88a.20192"},{"key":"2026051310150650678_j_almed-2025-0187_ref_008","doi-asserted-by":"crossref","unstructured":"Albertsen, PC. Screening for prostate cancer with prostate-specific antigen: the journey continues. Eur Urol 2023;83:110\u20131. https:\/\/doi.org\/10.1016\/j.eururo.2022.10.018.","DOI":"10.1016\/j.eururo.2022.10.018"},{"key":"2026051310150650678_j_almed-2025-0187_ref_009","unstructured":"PSA en el cribratge de c\u00e0ncer de pr\u00f2stata. Essencial, afegint valor a la pr\u00e0ctica cl\u00ednica. Departament de Salut. Generalitat de Catalunya. https:\/\/essencialsalut.gencat.cat\/ca\/detalls\/Article\/PSA_cribratge_cancer_prostata [Accessed 5 Nov 2025]."},{"key":"2026051310150650678_j_almed-2025-0187_ref_010","unstructured":"Gu\u00edaSalud. Recomendaciones de no hacer. https:\/\/portal.guiasalud.es\/no-hacer\/no-realizar-de-forma-sistematica-la-determinacion-de-psa-a-individuos-asintomaticos-sin-antecedentes-familiares-de-primer-grado-de-cancer-de-prostata\/ [Accessed 5 Nov 2025]."},{"key":"2026051310150650678_j_almed-2025-0187_ref_011","unstructured":"Estado de la evidencia y recomendaciones sobre actividades de cribado en el SNS. Ponencia de cribado poblacional de la Comisi\u00f3n de Salud P\u00fablica. Madrid: Ministerio de Sanidad, Consumo y Bienestar Social, Abril 2019."},{"key":"2026051310150650678_j_almed-2025-0187_ref_012","doi-asserted-by":"crossref","unstructured":"Brenes Berm\u00fadez, FJ, Alc\u00e1ntara Montero, A. Detecci\u00f3n precoz o cribado en la prevenci\u00f3n del c\u00e1ncer de pr\u00f3stata? Semergen 2017;43:100\u20138.","DOI":"10.1016\/j.semerg.2016.01.014"},{"key":"2026051310150650678_j_almed-2025-0187_ref_013","doi-asserted-by":"crossref","unstructured":"Marzo-Castillejo, M, Bellas-Beceiro, B, Vela-Vallesp\u00edn, C, Arana-Ballestara, Gallegoa, M, Navarroa, J, et al.. Grupos de expertos del PAPPS. Recomendaciones de prevenci\u00f3n del c\u00e1ncer. Aten Primaria 2014;46:24\u201341.","DOI":"10.1016\/S0212-6567(14)70049-6"},{"key":"2026051310150650678_j_almed-2025-0187_ref_014","unstructured":"Decisiones inteligentes desde el laboratorio: de elegir sabiamente a no hacer. Madrid: Asociaci\u00f3n Espa\u00f1ola de Biopatolog\u00eda M\u00e9dica-Medicina del Laboratorio, 2021."},{"key":"2026051310150650678_j_almed-2025-0187_ref_015","doi-asserted-by":"crossref","unstructured":"Livingston, CJ, Freeman, RJ, Mohammad, A, Costales, VC, Titus, TM, Harvey, BJ, et al.. Choosing wisely\u00ae in preventive medicine: the American college of preventive medicine\u2019s top 5 list of recommendations. Am J Prev Med 2016;51:141\u20139. https:\/\/doi.org\/10.1016\/j.amepre.2016.03.009.","DOI":"10.1016\/j.amepre.2016.03.009"},{"key":"2026051310150650678_j_almed-2025-0187_ref_016","doi-asserted-by":"crossref","unstructured":"Filella, X, Albaladejo, MD, Allu\u00e9, JA, Casta\u00f1o, MA, Morell-Garcia, D, Ruiz, M\u00c0, et al.. Prostate cancer screening: guidelines review and laboratory issues. Clin Chem Lab Med 2019;57:1474\u201387. https:\/\/doi.org\/10.1515\/cclm-2018-1252.","DOI":"10.1515\/cclm-2018-1252"},{"key":"2026051310150650678_j_almed-2025-0187_ref_017","doi-asserted-by":"crossref","unstructured":"Schr\u00f6der, FH, Hugosson, J, Roobol, MJ, Tammela, TL, Ciatto, S, Nelen, V, et al.. Screening and prostate-cancer mortality in a randomized European study. N\u00a0Engl J Med 2009;360:1320\u20138.","DOI":"10.1056\/NEJMoa0810084"},{"key":"2026051310150650678_j_almed-2025-0187_ref_018","doi-asserted-by":"crossref","unstructured":"Andriole, GL, Crawford, ED, Grubb, RL3rd, Buys, SS, Chia, D, Church, TR, et al.. Mortality results from a randomized prostate-cancer screening trial. N\u00a0Engl J Med 2009;360:1310\u20139. https:\/\/doi.org\/10.1056\/nejmoa0810696.","DOI":"10.1056\/NEJMoa0810696"},{"key":"2026051310150650678_j_almed-2025-0187_ref_019","doi-asserted-by":"crossref","unstructured":"Chou, R, Croswell, JM, Dana, T, Bougatsos, C, Blazina, I, Fu, R, et al.. Screening for prostate cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med 2011;155:762\u201371. https:\/\/doi.org\/10.7326\/0003-4819-155-11-201112060-00375.","DOI":"10.7326\/0003-4819-155-11-201112060-00375"},{"key":"2026051310150650678_j_almed-2025-0187_ref_020","doi-asserted-by":"crossref","unstructured":"Ilic, D, O\u2019Connor, D, Green, S, Wilt, TJ. Screening for prostate cancer: an updated cochrane systematic review. BJU Int 2011;107:882\u201391. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.10032.x.","DOI":"10.1111\/j.1464-410X.2010.10032.x"},{"key":"2026051310150650678_j_almed-2025-0187_ref_021","doi-asserted-by":"crossref","unstructured":"Ilic, D, Djulbegovic, M, Jung, JH, Hwang, EC, Zhou, Q, Cleves, A, et al.. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 2018;362. https:\/\/doi.org\/10.1136\/bmj.k3519.","DOI":"10.1136\/bmj.k3519"},{"key":"2026051310150650678_j_almed-2025-0187_ref_022","doi-asserted-by":"crossref","unstructured":"Bretthauer, M, Wieszczy, P, L\u00f8berg, M, Kaminski, MF, Werner, TF, Helsingen, LM, et al.. Estimated lifetime gained with cancer screening tests: a meta-analysis of randomized clinical trials. JAMA Intern Med 2023;183:1196\u2013203. https:\/\/doi.org\/10.1001\/jamainternmed.2023.3798.","DOI":"10.1001\/jamainternmed.2023.3798"},{"key":"2026051310150650678_j_almed-2025-0187_ref_023","doi-asserted-by":"crossref","unstructured":"Moyer, VA. USPTF. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012;157:120\u201334. https:\/\/doi.org\/10.7326\/0003-4819-157-2-201207170-00459.","DOI":"10.7326\/0003-4819-157-2-201207170-00459"},{"key":"2026051310150650678_j_almed-2025-0187_ref_024","doi-asserted-by":"crossref","unstructured":"Hugosson, J, Carlsson, S, Aus, G, Bergdahl, S, Khatami, A, Lodding, P, et al.. Mortality results from the g\u00f6teborg randomised population-based prostate cancer screening trial. Lancet Oncol 2010;11:725\u201332. https:\/\/doi.org\/10.1016\/s1470-2045(10)70146-7.","DOI":"10.1016\/S1470-2045(10)70146-7"},{"key":"2026051310150650678_j_almed-2025-0187_ref_025","doi-asserted-by":"crossref","unstructured":"Kjellman, A, Akre, O, Norming, U, Gustafsson, O. 15-year followup of a population based prostate cancer screening study. J\u00a0Urol 2009;181:1615\u201321. https:\/\/doi.org\/10.1016\/j.juro.2008.11.115.","DOI":"10.1016\/j.juro.2008.11.115"},{"key":"2026051310150650678_j_almed-2025-0187_ref_026","doi-asserted-by":"crossref","unstructured":"Labrie, F, Candas, B, Cusan, L, Gomez, JL, B\u00e9langer, A, Brousseau, G, et al.. Screening decreases prostate cancer mortality: 11-Year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004;59:311\u20138. https:\/\/doi.org\/10.1002\/pros.20017.","DOI":"10.1002\/pros.20017"},{"key":"2026051310150650678_j_almed-2025-0187_ref_027","doi-asserted-by":"crossref","unstructured":"Sandblom, G, Varenhorst, E, Lofman, O, Rosell, J, Carlsson, P. Clinical consequences of screening for prostate cancer: 15\u00a0years follow-up of a randomised controlled trial in Sweden. Eur Urol 2004;46:717\u201324. https:\/\/doi.org\/10.1016\/j.eururo.2004.08.011.","DOI":"10.1016\/j.eururo.2004.08.011"},{"key":"2026051310150650678_j_almed-2025-0187_ref_028","doi-asserted-by":"crossref","unstructured":"Sandblom, G, Varenhorst, E, Rosell, J, L\u00f6fman, O, Carlsson, P. Randomised prostate cancer screening trial: 20\u00a0year follow-up. BMJ 2011;342. https:\/\/doi.org\/10.1136\/bmj.d1539.","DOI":"10.1136\/bmj.d1539"},{"key":"2026051310150650678_j_almed-2025-0187_ref_029","doi-asserted-by":"crossref","unstructured":"Martin, RM, Donovan, JL, Turner, EL, Metcalfe, C, Young, GJ, Walsh, EI, et al.. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA 2018;319:883\u201395. https:\/\/doi.org\/10.1001\/jama.2018.0154.","DOI":"10.1001\/jama.2018.0154"},{"key":"2026051310150650678_j_almed-2025-0187_ref_030","doi-asserted-by":"crossref","unstructured":"Schr\u00f6der, FH, Hugosson, J, Roobol, MJ, Tammela, TL, Zappa, M, Nelen, V, et al.. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13\u00a0years of follow-up. Lancet 2014;384:2027.","DOI":"10.1016\/S0140-6736(14)60525-0"},{"key":"2026051310150650678_j_almed-2025-0187_ref_031","doi-asserted-by":"crossref","unstructured":"Lundgren, PO, Kjellman, A, Norming, U, Gustafsson, O. Long-term outcome of a single intervention population based prostate cancer screening study. J\u00a0Urol 2018;200:82\u20138. https:\/\/doi.org\/10.1016\/j.juro.2018.01.080.","DOI":"10.1016\/j.juro.2018.01.080"},{"key":"2026051310150650678_j_almed-2025-0187_ref_032","doi-asserted-by":"crossref","unstructured":"Andriole, GL, Crawford, ED, Grubb, RL3rd, Buys, SS, Chia, D, Church, TR, et al.. PLCO project team. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13\u00a0years of follow-up. J\u00a0Natl Cancer Inst 2012;104:125\u201332. https:\/\/doi.org\/10.1093\/jnci\/djr500.","DOI":"10.1093\/jnci\/djr500"},{"key":"2026051310150650678_j_almed-2025-0187_ref_033","doi-asserted-by":"crossref","unstructured":"Hugosson, J, Roobol, MJ, M\u00e5nsson, M, Tammela, TLJ, Zappa, M, Nelen, V, et al.. A 16-yr Follow-up of the European randomized study of screening for prostate cancer. Eur Urol 2019;76:43\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.009.","DOI":"10.1590\/s1677-5538.ibju.2020.03.06"},{"key":"2026051310150650678_j_almed-2025-0187_ref_034","doi-asserted-by":"crossref","unstructured":"Klotz, L. Overdiagnosis in urologic cancer: for world journal of urology symposium on active surveillance in prostate and renal cancer. World J Urol 2022;40:1\u20138. https:\/\/doi.org\/10.1007\/s00345-020-03523-2.","DOI":"10.1007\/s00345-020-03523-2"},{"key":"2026051310150650678_j_almed-2025-0187_ref_035","doi-asserted-by":"crossref","unstructured":"Loeb, S, Bjurlin, MA, Nicholson, J, Tammela, TL, Penson, DF, Carter, HB, et al.. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014;65:1046\u201355. https:\/\/doi.org\/10.1016\/j.eururo.2013.12.062.","DOI":"10.1016\/j.eururo.2013.12.062"},{"key":"2026051310150650678_j_almed-2025-0187_ref_036","doi-asserted-by":"crossref","unstructured":"Bandini, M, Mazzone, E, Preisser, F, Nazzani, S, Zaffuto, E, Marchioni, M, et al.. Increase in the annual rate of newly diagnosed metastatic prostate cancer: a contemporary analysis of the surveillance, epidemiology and end results database. Eur Urol Oncol 2018;1:314\u201320. https:\/\/doi.org\/10.1016\/j.euo.2018.04.013.","DOI":"10.1016\/j.euo.2018.04.013"},{"key":"2026051310150650678_j_almed-2025-0187_ref_037","doi-asserted-by":"crossref","unstructured":"Grossman, DC, Curry, SJ, Owens, DK, Bibbins-Domingo, K, Caughey, AB, Davidson, KW, et al.. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 2018;319:1901\u201313. https:\/\/doi.org\/10.1001\/jama.2018.3710.","DOI":"10.1001\/jama.2018.3710"},{"key":"2026051310150650678_j_almed-2025-0187_ref_038","doi-asserted-by":"crossref","unstructured":"Stephan, C, Klaas, M, M\u00fcller, C, Schnorr, D, Loening, SA, Jung, K, et al.. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006;52:59\u201364. https:\/\/doi.org\/10.1373\/clinchem.2005.059170.","DOI":"10.1373\/clinchem.2005.059170"},{"key":"2026051310150650678_j_almed-2025-0187_ref_039","doi-asserted-by":"crossref","unstructured":"Foj, L, Filella, X, Alcover, J, Aug\u00e9, JA, Escudero, JM, Molina, R, et al.. Variability of assay methods for total and free PSA after WHO standardization. Tumour Biol 2014;35:1867\u201373. https:\/\/doi.org\/10.1007\/s13277-013-1249-2.","DOI":"10.1007\/s13277-013-1249-2"},{"key":"2026051310150650678_j_almed-2025-0187_ref_040","doi-asserted-by":"crossref","unstructured":"Boegemann, M, Arsov, C, Hadaschik, B, Herkommer, K, Imkamp, F, Nofer, JR, et al.. Discordant prostate specific antigen test results despite WHO assay standardization. Int J Biol Markers 2018;33:275\u201382. https:\/\/doi.org\/10.1177\/1724600818754750.","DOI":"10.1177\/1724600818754750"},{"key":"2026051310150650678_j_almed-2025-0187_ref_041","doi-asserted-by":"crossref","unstructured":"Roobol, MJ, de Vos, II, M\u00e5nsson, M, Godtman, RA, Talala, KM, den Hond, E, et al.. European study of prostate cancer screening - 23-year Follow-up. N\u00a0Engl J Med 2025;393:1669\u201380. https:\/\/doi.org\/10.1056\/nejmoa2503223.","DOI":"10.1056\/NEJMoa2503223"},{"key":"2026051310150650678_j_almed-2025-0187_ref_042","doi-asserted-by":"crossref","unstructured":"Martin, RM, Turner, EL, Young, GJ, Metcalfe, C, Walsh, EI, Lane, JA, et al.. CAP trial group. prostate-specific antigen screening and 15-Year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial. JAMA 2024;331:1460\u201370. https:\/\/doi.org\/10.1001\/jama.2024.4011.","DOI":"10.1001\/jama.2024.4011"},{"key":"2026051310150650678_j_almed-2025-0187_ref_043","doi-asserted-by":"crossref","unstructured":"Grubb, RL, Pinsky, P, Prorok, PC, Andriole, GL. Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial. Eur Urol 2015;68:545\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2015.04.026.","DOI":"10.1016\/j.eururo.2015.04.026"},{"key":"2026051310150650678_j_almed-2025-0187_ref_044","doi-asserted-by":"crossref","unstructured":"Schr\u00f6der, FH, Roobol, MJ. ERSPC and PLCO prostate cancer screening studies: what are the differences? Eur Urol 2010;58:46\u201352.","DOI":"10.1016\/j.eururo.2010.03.033"},{"key":"2026051310150650678_j_almed-2025-0187_ref_045","doi-asserted-by":"crossref","unstructured":"Pinsky, PF, Prorok, PC, Yu, K, Kramer, BS, Black, A, Gohagan, JK, et al.. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15\u00a0years. Cancer 2017;123:592\u20139. https:\/\/doi.org\/10.1002\/cncr.30474.","DOI":"10.1002\/cncr.30474"},{"key":"2026051310150650678_j_almed-2025-0187_ref_046","doi-asserted-by":"crossref","unstructured":"Filella, X, Fern\u00e1ndez-Galan, E, Fern\u00e1ndez Bonifacio, R, Foj, L. Emerging biomarkers in the diagnosis of prostate cancer. Pharmgenomics Pers Med 2018;11:83\u201394. https:\/\/doi.org\/10.2147\/PGPM.S136026.","DOI":"10.2147\/PGPM.S136026"},{"key":"2026051310150650678_j_almed-2025-0187_ref_047","doi-asserted-by":"crossref","unstructured":"Van Poppel, H, Hogenhout, R, Albers, P, van den Bergh, RCN, Barentsz, JO, Roobol, MJ, et al.. Early detection of prostate cancer in 2020 and beyond: facts and recommendations for the European union and the European commission. Eur Urol 2021;79:327\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.010.","DOI":"10.1016\/j.eururo.2020.12.010"},{"key":"2026051310150650678_j_almed-2025-0187_ref_048","doi-asserted-by":"crossref","unstructured":"Van Poppel, H, Roobol, MJ, Chapple, CR, Catto, JWF, N\u2019Dow, J, S\u00f8nksen, J, et al.. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European association of urology position and recommendations for 2021. Eur Urol 2021;80:703\u201311. https:\/\/doi.org\/10.1016\/j.eururo.2021.07.024.","DOI":"10.1016\/j.eururo.2021.07.024"},{"key":"2026051310150650678_j_almed-2025-0187_ref_049","doi-asserted-by":"crossref","unstructured":"Filella, X, Gonz\u00e1lez, \u00c1, Aug\u00e9, JM, Barco, A, Carbonell, R, Gaspar, MJ, et al.. A new approach to prostate cancer screening. Adv Lab Med 2023;4:207\u201311. https:\/\/doi.org\/10.1515\/almed-2023-0082.","DOI":"10.1515\/almed-2023-0082"},{"key":"2026051310150650678_j_almed-2025-0187_ref_050","unstructured":"Proposal for a council recommendation on strengthening prevention through early detection: a new EU approach on cancer screening replacing council recommendation 2003\/878\/EC. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:52022DC0474 [Accessed 5 Nov 2025]."},{"key":"2026051310150650678_j_almed-2025-0187_ref_051","unstructured":"ANNEX to the proposal for a council recommendation on strengthening prevention through early detection: a new EU approach on cancer screening replacing council recommendation 2003\/878\/EC. https:\/\/health.ec.europa.eu\/publications\/annex-proposal-council-recommendation-cr-strengthening-prevention-through-early-detection-new_en [Accessed 5 Nov 2025]."},{"key":"2026051310150650678_j_almed-2025-0187_ref_052","unstructured":"PRAISE-U consortium. https:\/\/uroweb.org\/praise-u\/ [Accessed 19 Nov 2025]."},{"key":"2026051310150650678_j_almed-2025-0187_ref_053","doi-asserted-by":"crossref","unstructured":"Singh, D, Carvalho, AL, Mosquera, I, Vilaseca, J, Patasius, A, Miksiene, G, PRAISE-U consortium, et al.. Monitoring of prostate cancer screening in the European union: development of key performance indicators through the PRAISE-U project. eClinicalMedicine 2025;80. https:\/\/doi.org\/10.1016\/j.eclinm.2024.103022.","DOI":"10.1016\/j.eclinm.2024.103022"},{"key":"2026051310150650678_j_almed-2025-0187_ref_054","doi-asserted-by":"crossref","unstructured":"Chandran, A, van Harten, M, Singh, D, Vilaseca, J, Patasius, A, Tupikowski, K, et al.. Risk-stratified approach to implementing population-based prostate cancer screening in five pilot sites in the European union: a protocol for the PRAISE-U project. Eur Urol Open Sci 2024;70:8\u201317. https:\/\/doi.org\/10.1016\/j.euros.2024.09.003.","DOI":"10.1016\/j.euros.2024.09.003"},{"key":"2026051310150650678_j_almed-2025-0187_ref_055","doi-asserted-by":"crossref","unstructured":"Bratt, O, Godtman, RA, Jiborn, T, Wallstr\u00f6m, J, Akre, O, Carlsson, S, et al.. Population-based organised prostate cancer testing: results from the first invitation of 50-year-old men. Eur Urol 2024;85:207\u201314. https:\/\/doi.org\/10.1016\/j.eururo.2023.11.013.","DOI":"10.1016\/j.eururo.2023.11.013"},{"key":"2026051310150650678_j_almed-2025-0187_ref_056","doi-asserted-by":"crossref","unstructured":"Arsov, C, Albers, P, Herkommer, K, Gschwend, J, Imkamp, F, Peters, I, et al.. A randomized trial of risk-adapted screening for prostate cancer in young men-results of the first screening round of the PROBASE trial. Int J Cancer 2022;150:1861\u20139. https:\/\/doi.org\/10.1002\/ijc.33940.","DOI":"10.1002\/ijc.33940"},{"key":"2026051310150650678_j_almed-2025-0187_ref_057","unstructured":"Identificazione di un approccio multilivello per lo screening del tumore della prostata. https:\/\/www.regione.lombardia.it\/wps\/wcm\/connect\/88936da3-0e39-4d7d-bcb9-496ad7a6efed\/ddgw_15656_2024_istruzioni_operative_rev_all.pdf?MOD=AJPERES&CACHEID=ROOTWORKSPACE-88936da3-0e39-4d7d-bcb9-496ad7a6efed-pbTgBtf [Accessed 19 Nov 2025]."},{"key":"2026051310150650678_j_almed-2025-0187_ref_058","unstructured":"F Onda. Diagnosi precoce del tumore della prostate. Dalle raccomandazioni del Consiglio dell\u2019Unione Europea alle realt\u00e0 regionali. https:\/\/fondazioneonda.it\/ondauploads\/2025\/10\/All.-1_Documento-istituzionale_Tumore-della-prostata-e-nuove-raccomandazioni-europee.pdf [Accessed 19 Nov 2025]."},{"key":"2026051310150650678_j_almed-2025-0187_ref_059","doi-asserted-by":"crossref","unstructured":"Greene, KL, Albertsen, PC, Babaian, RJ, Carter, HB, Gann, PH, Han, M, et al.. Prostate specific antigen best practice statement: 2009 update. J\u00a0Urol 2009;182:2232\u201341. https:\/\/doi.org\/10.1016\/j.juro.2009.07.093.","DOI":"10.1016\/j.juro.2009.07.093"},{"key":"2026051310150650678_j_almed-2025-0187_ref_060","doi-asserted-by":"crossref","unstructured":"Heidenreich, A, Bastian, PJ, Bellmunt, J, Bolla, M, Joniau, S, van der Kwast, T, European Association of Urology, et al.. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124\u201337. https:\/\/doi.org\/10.1016\/j.eururo.2013.09.046.","DOI":"10.1016\/j.eururo.2013.09.046"},{"key":"2026051310150650678_j_almed-2025-0187_ref_061","doi-asserted-by":"crossref","unstructured":"Blijenberg, BG, Yurdakul, G, Van Zelst, BD, Bangma, CH, Wildhagen, MF, Schr\u00f6der, FH, et al.. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 2001;88:545\u201350. https:\/\/doi.org\/10.1046\/j.1464-410x.2001.02374.x.","DOI":"10.1046\/j.1464-410X.2001.02374.x"},{"key":"2026051310150650678_j_almed-2025-0187_ref_062","doi-asserted-by":"crossref","unstructured":"Kaufmann, B, Pellegrino, P, Zuluaga, L, Ben-David, R, M\u00fcntener, M, Keller, EX, et al.. Interassay variability and clinical implications of five different prostate-specific antigen assays. Eur Urol Open Sci 2024;63:4\u201312. https:\/\/doi.org\/10.1016\/j.euros.2024.03.008.","DOI":"10.1016\/j.euros.2024.03.008"}],"container-title":["Advances in Laboratory Medicine \/ Avances en Medicina de Laboratorio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/almed-2025-0187\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/almed-2025-0187\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:18:09Z","timestamp":1778667489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/almed-2025-0187\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":62,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,28]]},"published-print":{"date-parts":[[2026,5,12]]}},"alternative-id":["10.1515\/almed-2025-0187"],"URL":"https:\/\/doi.org\/10.1515\/almed-2025-0187","relation":{},"ISSN":["2628-491X"],"issn-type":[{"value":"2628-491X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}